Levocetirizine Oral Disintegrating Tablet: A Randomized Open‐Label Crossover Bioequivalence Study in Healthy Japanese Volunteers. Issue 7 (20th March 2020)

• Record Type: Journal Article
• Authors: Ino, Hiroko; Shiramoto, Masanari; Eto, Takashi; Haranaka, Miwa; Irie, Shin; Terao, Takumi; Ogura, Hirofumi; Wakamatsu, Akira; Hoyano, Keiko; Nakano, Atsushi
• Is Part Of: Clinical pharmacology in drug development. Volume 9:Issue 7(2020)
• Page Start: 805
• Page End: 812
• Publication Date: 2020-03-20
• Subjects: Levocetirizine -- cetirizine -- oral disintegrating tablet -- bioequivalence -- healthy Japanese male subjects -- single dose; Drugs -- Testing -- Periodicals; Drug development -- Periodicals; Clinical pharmacology -- Periodicals; 615.580724
• DOI: 10.1002/cpdd.791
• Languages: English
• ISSNs: 2160-7648

Abstract

Abstract: Levocetirizine is classified as a second‐generation antihistamine. Levocetirizine is available for the treatment of allergic disorders such as allergic rhinitis and chronic idiopathic urticaria. This was a single‐center, single‐dose, open‐label, randomized, 2‐way crossover study in healthy Japanese male subjects consisting of 2 parts. Part 1 compared the bioavailability of levocetirizine oral disintegrating tablet (ODT) and levocetirizine immediate‐release tablet (IRT) taken with water in the fasted state in 24 subjects; all subjects completed this part of the trial. In part 2, the bioavailability of levocetirizine ODT without water was compared with that of levocetirizine IRT with water in the fasted state in 48 subjects; 47 subjects completed this part of the trial. Bioequivalence was demonstrated between levocetirizine IRT 5 mg and ODT 5 mg. The safety profiles were generally similar between levocetirizine ODT and levocetirizine IRT, with no serious adverse events, deaths, or adverse events leading to withdrawal reported during the study.